翰思艾泰生物医药科技（武汉）股份有限公司（香港联交所股份代号：03378）于2026年6月29日进行股份回购，涉及数量37,200股，约占该事件前已发行股本的0.028%。本次回购的每股价格介乎26.30港元至27.92港元，合共付出约102.33万港元。回购完成后，公司已发行股本为134,592,830股，库藏股数量增至1,626,000股，总股本维持136,218,830股。
据公告，购回授权于2026年6月24日获得通过，授权总额度为13,469,683股。截至目前，共计104,000股已根据该授权被回购。回购完成后，后续任何新的股份发行或库藏股再次出售、转让需遵守暂止期安排，暂止期至2026年7月29日止。公司确认已符合法定程序及香港联交所相关上市规则的要求。本次公告由公司董事长兼执行董事张发明签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.